|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
ES2301198T3
(es)
|
1997-06-12 |
2008-06-16 |
Novartis International Pharmaceutical Ltd. |
Polipeptidos artificiales de anticuerpos.
|
|
DK1210425T4
(en)
|
1999-08-17 |
2015-08-10 |
Apotech R & D Sa |
BAFF receptor (BCMA), an immunoregulatory agent
|
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
MXPA02008265A
(es)
|
2000-02-24 |
2004-09-10 |
Xcyte Therapies Inc |
Concentracion y estimulacion simultanea de calulas.
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
WO2001096584A2
(en)
|
2000-06-12 |
2001-12-20 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
EP3363907A1
(en)
|
2004-05-27 |
2018-08-22 |
The Trustees of the University of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
PT2406284T
(pt)
|
2009-03-10 |
2016-09-29 |
Biogen Ma Inc |
Anticorpos anti-bcma
|
|
US20130273055A1
(en)
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
|
CA2832540C
(en)
|
2011-04-08 |
2020-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
LT3415531T
(lt)
|
2011-05-27 |
2023-09-25 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) – surišantys baltymai
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
WO2013126712A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
EP3689383A1
(en)
|
2012-04-11 |
2020-08-05 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
RU2673153C2
(ru)
|
2012-04-20 |
2018-11-22 |
АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи |
Полипептиды, связывающиеся с cd3
|
|
US10189906B2
(en)
|
2012-11-01 |
2019-01-29 |
Max-Delrück-Centrum Für Molekulare Medizin |
Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
|
|
US9243058B2
(en)
|
2012-12-07 |
2016-01-26 |
Amgen, Inc. |
BCMA antigen binding proteins
|
|
US20160008399A1
(en)
|
2013-01-14 |
2016-01-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
|
|
EP2953972B1
(en)
|
2013-02-05 |
2020-07-08 |
EngMab Sàrl |
Method for the selection of antibodies against bcma
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
EP3102609A4
(en)
|
2014-02-04 |
2017-08-23 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
RU2741899C2
(ru)
|
2014-04-25 |
2021-01-29 |
Блубёрд Био, Инк. |
Улучшенные способы производства средств адоптивной клеточной терапии
|
|
EP3998278A1
(en)
|
2014-04-25 |
2022-05-18 |
2seventy bio, Inc. |
Mnd promoter chimeric antigen receptors
|
|
IL248257B1
(en)
|
2014-04-30 |
2024-04-01 |
Max Delbruck Centrum Fur Molekulare Medizin In Der Helmholtz Gemeinschaft |
Human antibodies against CD269(BCMA)
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
KR20230008915A
(ko)
|
2014-06-06 |
2023-01-16 |
2세븐티 바이오, 인코포레이티드 |
개선된 t 세포 조성물
|
|
MX2017001011A
(es)
*
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
|
CA2956002C
(en)
|
2014-07-24 |
2023-06-27 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US20180334490A1
(en)
*
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SG11201704549UA
(en)
|
2014-12-05 |
2017-07-28 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
RS61781B1
(sr)
|
2014-12-05 |
2021-06-30 |
Memorial Sloan Kettering Cancer Center |
Antitela koja ciljaju antigen za sazrevanje b-ćelija i postupci upotrebe
|
|
BR112017012502B1
(pt)
|
2014-12-12 |
2020-09-15 |
Bluebird Bio, Inc. |
Polinucleotídeo, polipeptídeo de car codificado pelo dito polinucleotídeo, vetor compreendendo o dito polinucleotídeo, composição compreendendo o dito vetor e método para geração de uma célula imune efetora compreendendo um car
|
|
WO2016130598A1
(en)
|
2015-02-09 |
2016-08-18 |
University Of Florida Research Foundation, Inc. |
Bi-specific chimeric antigen receptor and uses thereof
|
|
JP2018510160A
(ja)
|
2015-03-20 |
2018-04-12 |
ブルーバード バイオ， インコーポレイテッド |
ベクター製剤
|
|
EP3283520B1
(en)
|
2015-04-13 |
2020-05-06 |
Pfizer Inc |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
TWI787645B
(zh)
|
2015-04-13 |
2022-12-21 |
美商輝瑞股份有限公司 |
Ｃｄ３特異性抗體、治療性雙特異性抗體及其用途
|
|
CN115058395A
(zh)
|
2015-06-25 |
2022-09-16 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
AU2016293942B2
(en)
|
2015-07-10 |
2022-06-16 |
Merus N.V. |
Human CD3 binding antibody
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
PT3331910T
(pt)
|
2015-08-03 |
2020-03-24 |
Engmab Sarl |
Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
MX2018002043A
(es)
|
2015-08-17 |
2018-07-06 |
Janssen Pharmaceutica Nv |
ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
|